Aromatherapy for Pain, Emotional Distress and Sleep Quality in Cancer Patients Receiving Hospice Care: A Meta-Analysis

**Feng-Yi Lai**, RN, MSN, Instructor Department of Nursing, *Shu-Zen College of Medicine and Management,* **Asphodel Yang**, RN, PhD, Associate Professor Department of Nursing, Central Taiwan University of Science & Technology

# Background

- Cancer has been the No. 1 leading cause of death for the past 30+ years in Taiwan.
- Individuals with cancer not only experience physiological discomforts but also psychological disturbances.
- In addition to conventional medical therapies, complementary therapies are also widely accepted.
- Aromatherapy is now one of the mostly used therapies in palliative care unit

#### **Pain in Patients With Cancer**

- is one of the most feared and burdensome symptoms.
- A metaanalysis of pain prevalence by van den Beuken-van Everdingen, de Rijke, Kessels, Schouten, van Kleef & Patijn in 2007:
  - 53% (95% CI = 43% to 63%) of patients at all disease stages
  - Of the patients with pain, > 1/3 graded their pain as moderate or severe.
- > 50% continue to experience pain with pain treatment

#### Emotional Disturbance in Patients With Cancer

- Prevalence reported from different studies ranged from 15-77%, as cancer advanced, the prevalence increased.
- Depression and anxiety are most seen psychological status.
- pharmacological management is the primary intervention

# Sleep Disturbance in Patients With Cancer

- 30-50% complain sleep disturbance
- Related factors include fatigue, altered emotion, pain and anxiety
- Pharmacological management is the primary choice of treatment
- Cognitive behavioral therapy is also used, but with its limitations.

## Aromatherapy

- the practice of using the natural oils extracted from flowers, bark, stems, leaves, roots or other parts of a plant to enhance psychological and physical well-being.
- A form of alternative medicine, aromatherapy is gaining momentum.
- used for a variety of applications
  - pain relief
  - mood enhancement
  - increased cognitive function


#### Aromatherapy

- Evidences show benefits of aromatherapy in:
  - Sleep quality (Brownfield, 1998; Lewith, Godfrey, & Prescott, 2005)
  - Pain (Soon, Hwuang, Sun, Wang, Chang , 2005; Anderson, Balchin, & Smith, 2000; Ro, Ha, Kim,& Yeom, 2002)
  - Stress/Anxiety ( (Chiu, 2003; Imura, Misao, & Ushijima, 2006; Kite et al., 1998; Wilkinson, Aldridge, Salmon, Cain, & Wilson, 1999)

# **Purpose of This Study**

 Using a metaanalysis approach to determine the effects of aromatherapy on (a) pain, (b) emotional distress and (c) sleeping quality in cancer patients receiving hospice care

#### Step 1: Ask An Answerable Question (A PICO Question)



#### Criteria for considering studies for this review

# Step 2: Tracking down the best evidence with which to answer that question

#### **Inclusion Criteria**

- Studies published in 1967 2011
- RCTs or CCTs
  - Non-randomized controlled trials and before and after studies will be considered in the absence of RCTs
- Individuals with cancer and receiving hospice care as study participants
- Used aromatherapy as intervention
- Pain, sleep quality and/or emotional distress as study outcome(s)
- Study reported necessary data for conducting metaanalysis

#### **Exclusion Criteria**

- Studies were conducted with cancer patient who were not at hospice care
- Systematic review
- Duplicate studies (only one study would be included in final data analyses)

# Search strategy

#### Electronic search

- A total of 7 databases were searched
- English
  - CINAHL
  - MEDLINE

Hand search

The Cochrane Library

#### Chinese

- National Digital Library of Theses and Dissertations in Taiwan (NDLTD)
- Index to Taiwan Periodical Literature System (PerioPath)
- Chinese Electronic Periodical Services
- Government Research Bulletin

# Keywords Used

- All terms in both Chinese and English
  - Aromatherapy
  - Cancer patients
  - Hospice care
  - Pain
  - Sleep Quality
  - Emotional distress
- MeSH database to determine any synonymous
- Boolean operator were used

#### **MeSH Terms**

Keywords	Mesh Database
Aromatherapy	Aromatherapy
Hospice Care	Hospice End Of Life Terminal Care Palliative Care
Pain	Chronic Pain
Emotional Distress	Depression Irritable Mood Anxiety
Sleep Quality	Insomnia Sleep Disturbance


#### **Selection Of Studies**

- One review author screened the title, abstract and descriptors of identified studies for possible inclusion.
- From the full text, two authors independently assessed potentially eligible trials for inclusion
- Differences were resolved by consensus, or 3dr third party adjudication.
- 8 studies were included in the final data analysis

#### **Results of study selection**

Database	No. of hits	No. met inclusion criteria	No. of duplication and were deleted	No. included in final appraisal
CINAHL	79	7	0	7
MEDLINE	4	4	3	1
Cochrane Library	14	13	13	0
CEPS	39	Ο	0	0
GRB	39	Ο	0	0
NTLTD in Taiwan	63	Ο	0	0
PerioPath	10	Ο	0	0
Total	248	24	16	8

#### **Flow Diagram for Study Selection**



Step 3: Critically appraising that evidence for its validity, impact, and applicability


#### Assessment Of Methodological Quality

- Methodological qualities of included studies were evaluated using The Cochrane Collaboration's Tool for Assessing Risk of Bias(2009)
  - A domain-based evaluation tool
    - 'Low risk' of bias
    - 'High risk' of bias
    - 'Unclear risk' of bias
  - 2 reviewers critically appraised each included studies, independently.
  - Inter-rater Kappa ranged 41.5~81% (p < .05)</p>

#### The Cochrane Collaboration's Tool for Assessing Risk of Bias


Selection bias	<ul><li>Random sequence generation.</li><li>Allocation concealment.</li></ul>
Performance bias	• Blinding of participants and personnel
Detection bias	Blinding of outcome assessment
Attrition bias	Incomplete outcome data
Reporting Bias	Selective reporting
Other Bias	• Other sources of bias

#### **Quality of Included Study**



Moderate level o f quality for included studies

# **Quality of Included Study**



Step 4: Synthesize the available evidence

#### **Data Collection**

- Data extracted from the publications included
  - Study design
  - Intervention
  - Participants' characteristics
  - methodological quality
  - outcome measures
- Data were extracted using a pre-tested extraction form by two independent reviewers

#### Data Analysis


- Comprehensive Meta Analysis version 2.2 (Biostate, 2006) was used to analysis statistical data extracted from retrieved articles and to conduct meta-analysis.
  - i.e., sample size, mean, change score, SD, *t*, *p* values
- Assessment of heterogeneity between studies
- Effects of aromatherapy on study outcomes
  - Standard difference in mean, 95% confidence intervals (CI) and *p*-values were calculated for each of studies as well as combined effects.

#### **Result: Effect On Pain**

Model Test of null (2-Tail)				Heter	ogeneity	11 13	1	Tau-squ		
	Z-value	P-value	Q-value	$df\left(Q\right)$	P-value	I-squared	Tau Squared	Standard Error	Variance	Tau
Fixed	2.885	0.004	4.037	2	0.133	50.452	0.111	0.220	0.048	0.333
Random	1.820	0.069			z Gentr	TAX.	160			

lodel	Study name			Statistics f	or each s	tudy			
		Std diff means	Standard error	Variance	Lower limit	Upper limit	Z-Value	p-Value	
	Chang, 2008	0.947	0.277	0.077	0.404	1.490	3.418	0.001	
	Louise et al., 2002	0.141	0.343	0.118	-0.532	0.814	0.410	0.682	
	Soden et al., 2004	0.268	0.375	0.141	-0.467	1.003	0.714	0.475	
Fixed		0.539	0.187	0.035	0.173	0.906	2.885	0.004	

Std diff in means and 95% CI



Favours A


Favours B

#### **Result: Effect On Sleep Quality**

Model	Test of m	ıll (2-Tail)		Heter	ogeneity		Tau-squared			
	Z-value	P-value	Q-value	$df\left(Q\right)$	P-value	I-squared	Tau Squared	Standard Error	Variance	Tau
Fixed	6.706	< 0.001	89.814	4	< 0.001	95.546	1.522	1.325	1.756	1.234
Random	1.087	0.277								

Model	Study name			Statistics f	or each si	tudy			
		Std diff in means	Standard error	Variance	Lower limit	Upper limit	Z-Value	p-Value	
	Louise et al., 2002	-0.052	0.343	0.118	-0.724	0.621	-0.150	0.880	
	Soden et al., 2004	2.707	0.516	0.266	1.697	3.717	5.251	0.000	
	Wilcock et al., 2004	-1.047	0.314	0.099	-1.663	-0.431	-3.329	0.001	_
	Wilkinson et al., 1999	0.060	0.214	0.046	-0.360	0.481	0.281	0.779	
	Wilkinson et al., 2007	1.595	0.163	0.026	1.276	1.914	9.799	0.000	
Fixed		0.741	0.111	0.012	0.525	0.958	6.706	0.000	
Random		0.621	0.571	0.326	-0.498	1.739	1.087	0.277	





Control

Experimental

#### **Result: Effect On Anxiety**

		14/1		1.023		
Model	Test of m	ıll (2 <b>-</b> Tail)	XIII	Hetero		
	- Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Fixed	-6.160	<.001	73.325	4	<.001	94.545
Random	-1.000	0.317				

Model	Study name			Statistics f	or each st	tudy				Std diff	in means and	95% CI	
		Std diff in means	Standard error	Variance	Lower limit	Upper limit	Z-Value	p-Value					
	Chang, 2008	0.444	0.266	0.071	-0.077	0.965	1.669	0.095			<b>-</b>	<b>⊢</b>	
	Kite et al., 1998	-0.344	0.187	0.035	-0.711	0.023	-1.839	0.066		I —	▰┤		
	Soden et al., 2004	-0.905	0.392	0.154	-1.673	-0.137	-2.310	0.021					
	Wilkinson et al., 1999	0.279	0.215	0.046	-0.144	0.701	1.293	0.196				-	
	Wilkinson et al., 2007	-1.618	0.163	0.027	-1.938	-1.297	-9.904	0.000		-			
Fixed		-0.592	0.096	0.009	-0.780	-0.404	-6.160	0.000					
Random		-0.428	0.428	0.184	-1.268	0.411	-1.000	0.317					
									-2.00	-1.00	0.00	1.00	2.00

Experimental

Control

#### **Result: Effect On Depression**

Model	Test of nu	ll (2-Tail)	(2-Tail) Heterogeneity							
	Z-value	P-value	Q-value	$df\left(Q\right)$	P-value	I-squared				
Fixed	-5.823	< 0.001	125.656	6	<.001	95.225				
Random	-0.459	0.646								

Model	Study name			Statistics f	for each s	tudy				Std dif	f in means and	95% CI	
		Std diff in means	Standard error	Variance	Lower limit	Upper limit	Z-Value	p-Value					
	Chang, 2008	2.363	0.342	0.117	1.692	3.034	6.903	0.000				1	
	Kite et al., 1998	-0.412	0.188	0.035	-0.780	-0.044	-2.195	0.028		I —	━─		
	Louise et al., 2002	-0.337	0.345	0.119	-1.014	0.340	-0.974	0.330					
	Soden et al., 2004	-0.905	0.392	0.154	-1.673	-0.137	-2.310	0.021	I —		<u> </u>		
	Wilcock et al., 2004	-0.478	0.299	0.089	-1.064	0.109	-1.597	0.110			∎──┼		
	Wilkinson et al., 1999	0.085	0.215	0.046	-0.335	0.506	0.398	0.691					
	Wilkinson et al., 2007	-1.618	0.163	0.027	-1.938	-1.297	-9.904	0.000		-			
Fixed		-0.527	0.090	0.008	-0.704	-0.349	-5.823	0.000					
Random		-0.198	0.432	0.187	-1.045	0.649	-0.459	0.646				-	
									-2.00	-1.00	0.00	1.00	2.00

Experimental

Control

#### Discussion

#### Limitations of the study

- Publication bias
  - Inconsistent results of Funnel Plot, Egger Regression and Fail –Safe Number
- Study quality
  - Non-RCT
  - Blinding
  - Small sample size
- Confounding factors
  - Homogeneity in population?

#### **Publication Bias**

	Pain	Anxiety	Depression	Sleep Quality
Funnel Plot	×	$\checkmark$	×	$\checkmark$
Egger Regression > .05	×	×	×	×
N.f.s > Tolerance Level	$\checkmark$	×	×	×
# of observed studies	3	5	7	5
# of studies needed to correct publication bias	3	28	18	32

" $\checkmark$ " meeting criterion : "x" Not meeting criterion

#### Bonus: From a Qualitative Perspective

- Dunwoody L ; Smyth A ; Davidson R (2002)
- Participants (n = 11: 10 females) were interviewed
  - at the time they just finished a block of six 1 hour once weekly sessions of aromatherapy
- Focus group
  - Using semi-structured interview

#### Bonus: From a Qualitative Perspective

Eight themes emerged from the analysis



negative aspects of the service

concerned with security of context (where the aromatherapy took place)

#### Conclusion

- The current strength of evidence is weak and more well-designed studies are strongly recommended.
- Clinical application should take individuals' differences into consideration